Tim Anderson
Stock Analyst at B of A Securities
(2.57)
# 2,122
Out of 5,182 analysts
50
Total ratings
51.85%
Success rate
2.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tim Anderson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JNJ Johnson & Johnson | Maintains: Neutral | $220 → $221 | $240.97 | -8.29% | 10 | Jan 22, 2026 | |
| LLY Eli Lilly and Company | Maintains: Buy | $1,286 → $1,268 | $927.06 | +36.78% | 2 | Dec 15, 2025 | |
| MRK Merck & Co. | Maintains: Buy | $105 → $120 | $120.85 | -0.70% | 5 | Dec 15, 2025 | |
| BMY Bristol-Myers Squibb Company | Upgrades: Buy | $52 → $61 | $59.33 | +2.81% | 2 | Dec 15, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Underperform | $543 → $627 | $763.04 | -17.83% | 3 | Oct 29, 2025 | |
| PFE Pfizer | Maintains: Neutral | $28 → $30 | $27.83 | +7.80% | 3 | Oct 3, 2025 | |
| AMGN Amgen | Maintains: Underperform | $261 → $272 | $342.57 | -20.60% | 6 | Sep 26, 2025 | |
| APGE Apogee Therapeutics | Maintains: Buy | $78 → $87 | $84.01 | +3.56% | 1 | Aug 28, 2025 | |
| AARD Aardvark Therapeutics | Maintains: Buy | $26 → $25 | $4.13 | +505.33% | 3 | Aug 28, 2025 | |
| ABBV AbbVie | Maintains: Neutral | $200 → $204 | $206.69 | -1.30% | 7 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $116 → $126 | $140.13 | -10.08% | 3 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $41 → $34 | $48.77 | -30.29% | 2 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $178 | $172.34 | +3.28% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $152.84 | - | 1 | May 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $202.83 | - | 1 | Sep 22, 2017 |
Johnson & Johnson
Jan 22, 2026
Maintains: Neutral
Price Target: $220 → $221
Current: $240.97
Upside: -8.29%
Eli Lilly and Company
Dec 15, 2025
Maintains: Buy
Price Target: $1,286 → $1,268
Current: $927.06
Upside: +36.78%
Merck & Co.
Dec 15, 2025
Maintains: Buy
Price Target: $105 → $120
Current: $120.85
Upside: -0.70%
Bristol-Myers Squibb Company
Dec 15, 2025
Upgrades: Buy
Price Target: $52 → $61
Current: $59.33
Upside: +2.81%
Regeneron Pharmaceuticals
Oct 29, 2025
Maintains: Underperform
Price Target: $543 → $627
Current: $763.04
Upside: -17.83%
Pfizer
Oct 3, 2025
Maintains: Neutral
Price Target: $28 → $30
Current: $27.83
Upside: +7.80%
Amgen
Sep 26, 2025
Maintains: Underperform
Price Target: $261 → $272
Current: $342.57
Upside: -20.60%
Apogee Therapeutics
Aug 28, 2025
Maintains: Buy
Price Target: $78 → $87
Current: $84.01
Upside: +3.56%
Aardvark Therapeutics
Aug 28, 2025
Maintains: Buy
Price Target: $26 → $25
Current: $4.13
Upside: +505.33%
AbbVie
Apr 28, 2025
Maintains: Neutral
Price Target: $200 → $204
Current: $206.69
Upside: -1.30%
Mar 5, 2025
Maintains: Buy
Price Target: $116 → $126
Current: $140.13
Upside: -10.08%
Feb 11, 2025
Maintains: Underperform
Price Target: $41 → $34
Current: $48.77
Upside: -30.29%
Dec 10, 2024
Reinstates: Neutral
Price Target: $178
Current: $172.34
Upside: +3.28%
May 9, 2022
Downgrades: Peer Perform
Price Target: n/a
Current: $152.84
Upside: -
Sep 22, 2017
Upgrades: Outperform
Price Target: n/a
Current: $202.83
Upside: -